Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Radiation for Prostate Cancer with Rising PSA
NCT00348816Phase 2Terminated
- Sponsor
- UT Health San Antonio
- Start
- May 2006
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by UT Health San Antonio. Primary endpoint: Rate of Prostate-Specific Antigen (PSA) Decline Reported as the Number of Subjects Reaching a PSA Nadir of Zero at 5 years. Started May 2006; status: terminated.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00348816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00348816.